PharmaEssentia Corporation
6446
Rang in aandelen
#1418
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Aandeelprijs
$37.84
Marktkapitalisatie
$15.65B
Verandering (1 dag)
-4.42%
Verandering (1 jaar)
149.23%
Land
TW
Handel PharmaEssentia Corporation (6446)
Categorie
Healthcare
EPS voor PharmaEssentia Corporation (6446)
EPS per June 2026 TTM: $0.63
Volgens de laatste financiële rapporten en de aandelenkoers van PharmaEssentia Corporation is de huidige EPS van het bedrijf (TTM) $0.63. Eind 2023 had het bedrijf een EPS van $-0.06, een daling ten opzichte van de EPS van 2022 die $-0.14 bedroeg.
EPS-geschiedenis van PharmaEssentia Corporation van 2010 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $0.63 | 153.00% |
| 2024 | $0.25 | -534.22% |
| 2023 | $-0.06 | -60.15% |
| 2022 | $-0.14 | -59.50% |
| 2021 | $-0.35 | 37.91% |
| 2020 | $-0.25 | 119.47% |
| 2019 | $-0.12 | -14.95% |
| 2018 | $-0.14 | 15.09% |
| 2017 | $-0.12 | 5.89% |
| 2016 | $-0.11 | -6.67% |
| 2015 | $-0.12 | -4.08% |
| 2014 | $-0.13 | 25.60% |
| 2013 | $-0.10 | 63.82% |
| 2012 | $-0.06 | 25.36% |
| 2011 | $-0.05 | 16.87% |
| 2010 | $-0.04 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | -12.05% |
IN
|
